New research from Yale University reveals that the experimental cancer drug AZD05030 blocks damage triggered during the formation of amyloid-beta plaques, restoring synaptic connections and memory in a mouse model of Alzheimer’s.
Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer’s given an experimental cancer drug, Yale School of Medicine researchers reported in the journal Annals of Neurology.
The drug, AZD05030, developed by Astra Zeneca proved disappointing in treating solid tumors but appears to block damage triggered during the formation of amyloid-beta plaques, a hallmark of Alzheimer’s disease. The new study, funded by an innovative National Institutes of Health (NIH) program to test failed drugs on different diseases, has led to the launch of human trials to test the efficacy of AZD05030 in Alzheimer’s patients.
“With this treatment, cells under bombardment by beta amyloid plaques show restored synaptic connections and reduced inflammation, and the animal’s memory, which was lost during the course of the disease, comes back,” said Stephen M. Strittmatter, the Vincent Coates Professor of Neurology and senior author of the study.
In the last five years, scientists have developed a more complete understanding of the complex chain of events that leads to Alzheimer’s disease. The new drug blocks one of those molecular steps, activation of the enzyme FYN, which leads to the loss of synaptic connections between brain cells. Several other steps in the disease process have the potential to be targets for new drugs, Strittmatter said.
“The speed with which this compound moved to human trials validates our New Therapeutic Uses program model and serves our mission to deliver more treatments to more patients more quickly,” said Dr. Christopher P. Austin, director of NIH’s National Center for Advancing Translational Sciences (NCATS), which funded the work.
Yale’s Christopher H. van Dyck, a co-author of the paper, and Strittmatter have initiated a multi-site clinical trial to determine whether the drug can also benefit Alzheimer’s patients. For more information on this trial being directed by van Dyck, visit http://www.adcs.org/studies/Connect.aspx or https://clinicaltrials.gov (NCT02167256 and NCT01864655).
The study was funded by the NCATS and the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director.
Publication: Adam C. Kaufman, et al., “Fyn inhibition rescues established memory and synapse loss in Alzheimer mice,” Annals of Neurology, 2015; DOI: 10.1002/ana.24394
Source: Bill Hathaway, Yale University
Image: Yale University